Cargando…
New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview
Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurren...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250389/ https://www.ncbi.nlm.nih.gov/pubmed/32508634 http://dx.doi.org/10.3389/fphar.2020.00655 |
_version_ | 1783538753535475712 |
---|---|
author | Valenzuela, Rodrigo A. Flores, Iván Urrutia, Beatriz Fuentes, Francisca Sabat, Pablo E. Llanos, Carolina Cuitino, Loreto Urzua, Cristhian A. |
author_facet | Valenzuela, Rodrigo A. Flores, Iván Urrutia, Beatriz Fuentes, Francisca Sabat, Pablo E. Llanos, Carolina Cuitino, Loreto Urzua, Cristhian A. |
author_sort | Valenzuela, Rodrigo A. |
collection | PubMed |
description | Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU. |
format | Online Article Text |
id | pubmed-7250389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72503892020-06-05 New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview Valenzuela, Rodrigo A. Flores, Iván Urrutia, Beatriz Fuentes, Francisca Sabat, Pablo E. Llanos, Carolina Cuitino, Loreto Urzua, Cristhian A. Front Pharmacol Pharmacology Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-α inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU. Frontiers Media S.A. 2020-05-08 /pmc/articles/PMC7250389/ /pubmed/32508634 http://dx.doi.org/10.3389/fphar.2020.00655 Text en Copyright © 2020 Valenzuela, Flores, Urrutia, Fuentes, Sabat, Llanos, Cuitino and Urzua http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Valenzuela, Rodrigo A. Flores, Iván Urrutia, Beatriz Fuentes, Francisca Sabat, Pablo E. Llanos, Carolina Cuitino, Loreto Urzua, Cristhian A. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title | New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title_full | New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title_fullStr | New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title_full_unstemmed | New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title_short | New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview |
title_sort | new pharmacological strategies for the treatment of non-infectious uveitis. a minireview |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250389/ https://www.ncbi.nlm.nih.gov/pubmed/32508634 http://dx.doi.org/10.3389/fphar.2020.00655 |
work_keys_str_mv | AT valenzuelarodrigoa newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT floresivan newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT urrutiabeatriz newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT fuentesfrancisca newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT sabatpabloe newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT llanoscarolina newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT cuitinoloreto newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview AT urzuacristhiana newpharmacologicalstrategiesforthetreatmentofnoninfectiousuveitisaminireview |